A pan‐inflammatory microRNA‐cluster is associated with orbital non‐Hodgkin lymphoma and idiopathic orbital inflammation

Laban, Kamil G.; Kalmann, Rachel; Bekker, Cornelis P. J.; Hiddingh, Sanne; Veen, Rob L. P. van der; Eenhorst, Christine A.E.; Genders, Stijn W.; Mourits, Maarten P.; Verhagen, Fleurieke H.; Leijten, Emmerik F A; Haitjema, Saskia; Groot, Mark de; Radstake, Timothy R. D. J.; Boer, Joke H. de; Kuiper, Jonas J.W.

doi:10.1002/eji.201948343

Cited by 9 publications

(8 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, only two studies have reported miRNA profiles of orbital malignant lymphoma, including diffuse large B-cell lymphoma [54,55]. Recently, Laban et al showed that seven (miR-140-5p, miR-148a-3p, miR193a-5p, miR-223-3p, miR-29a-3p, miR-365a-3p, and U6 snRNA) of 399 miRNAs analyzed in a panel were upregulated in the serum of patients with non-Hodgkin lymphomas, including diffuse large B-cell lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Distinctive Tissue and Serum MicroRNA Profile of IgG4-Related Ophthalmic Disease and MALT Lymphoma

Nezu

Usui

Asakage

et al. 2020

JCM

View full text Add to dashboard Cite

The molecular pathogenesis of orbital lymphoproliferative disorders, such as immunoglobulin G4-related ophthalmic disease (IgG4-ROD) and orbital mucosa-associated lymphoid tissue (MALT) lymphoma, remains essentially unknown. Differentiation between the two disorders, which is important since the work-up and treatment can vary greatly, is often challenging due to the lack of specific biomarkers. Although miRNAs play an important role in the regulation of carcinogenesis and inflammation, the relationship between miRNA and orbital lymphoproliferative diseases remains unknown. We performed a comprehensive analysis of 2565 miRNAs from biopsy and serum specimens of 17 cases with IgG4-ROD, where 21 cases with orbital MALT lymphoma were performed. We identified specific miRNA signatures and their miRNA target pathways, as well as the network analysis for IgG4-ROD and orbital MALT lymphoma. Machine-learning analysis identified miR-202-3p and miR-7112-3p as the best discriminators of IgG4-ROD and orbital MALT lymphoma, respectively. Enrichment analyses of biological pathways showed that the longevity-regulating pathway in IgG4-ROD and the mitogen-activated protein kinase (MAPK) signaling pathway in orbital MALT lymphoma was most enriched by target genes of downregulated miRNAs. This is the first evidence of miRNA profiles of biopsy and serum specimens of patients with IgG4-ROD and orbital MALT lymphoma. These data will be useful for developing diagnostic and therapeutic interventions, as well as elucidating the pathogenesis of these disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Distinctive Tissue and Serum MicroRNA Profile of IgG4-Related Ophthalmic Disease and MALT Lymphoma

Nezu

Usui

Asakage

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRNAs) are small noncoding regulatory RNAs whose compositional changes are associated with human pathophysiological processes, such as inflammation and cancer, etc. Bashant et al identified a paninflammatory miRNA-cluster, especially miR-223, that was upregulated in patients with OIP compared to controls [ 54 ]. MiR-223 derived from neutrophils in blood is a significant source of serum miRNAs [ 55 ].…”

Section: Etiopathogenesismentioning

confidence: 99%

“…MiR-223 derived from neutrophils in blood is a significant source of serum miRNAs [ 55 ]. In addition, a positive correlation was shown between the size of neutrophil cells and serum miR-223 levels in OIP patients [ 54 ]. These analyses suggested that changes in blood leukocyte composition may underlie increased miRNA clusters in blood in patients with OIP and that serum miRNA clusters correlate with neutrophil status.…”

Section: Etiopathogenesismentioning

confidence: 99%

Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment

Fang,

Shen,

Dai

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Orbital inflammatory pseudotumor (OIP) is a benign, non-specific inflammatory disorder that commonly occurs in middle-aged adults and is usually unilateral but can occur bilaterally. Its clinical manifestations have tremendous clinical heterogeneity and vary according to the site of infiltration and the degree of lesions, including orbital pain, swelling, diplopia, proptosis, restricted eye movement, and decreased visual acuity. Clinical features, Image characteristics and pathological examinations often need to be evaluated to confirm the diagnosis. Currently, there is no systematic research on the pathogenesis of OIP, which may be related to immunity or infection. The first-line treatment is glucocorticoids. Radiotherapy, immunosuppressants, and biologics can be considered for treatment-resistant, hormone-dependent, or intolerant patients. In this review, we aim to summarize and focus on new insights into OIP, including new diagnostic criteria, pathogenesis, and discoveries in new drugs and treatment strategies. In particular, we highlight the literature and find that T cell-mediated immune responses are closely related to the pathogenesis of OIP. Further exploration of the mechanism and signaling pathway of T cells in the immune process will help to identify their therapeutic targets and carry out targeted therapy to treat refractory OIP and reduce the side effects of traditional treatments.

show abstract

“…Several investigators suggested that the development of lymphoma, especially EMZL, may be associated with longterm chronic infections of the patients, such as chlamydia infection, helicobacter pylori infection, and chronic hepatitis [25][26][27][28] . The immune status was also considered to be associated with the development of orbital lymphoma [29][30] .…”

Section: Orbital Lymphoma Clinical Characteristicsmentioning

confidence: 99%

Predicting the prognosis of primary orbital lymphoma by clinical characteristics and imaging features

Zhu¹,

Zhang²,

Wang³

2023

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To analyze the 5-year disease-free survival (DFS) of primary orbital lymphoma (POL) by clinical characteristics and imaging features. METHODS: A total of 72 patients, 43 males and 29 females, with histologically confirmed POL, were retrospectively recruited between January 2012 and May 2017. The information on clinical characteristics, imaging features, and 5-year DFS was obtained. Univariate and multivariate forward logistic regression analyses were used to identify the variables significantly associated with 5-year DFS. Kaplan-Meier was applied for survival analysis. RESULTS: Univariate analysis revealed that uni- or bilateral orbital involvement, single or multiple lesions, treatment methods, and contrast enhancement pattern on images were significant for 5-year DFS (P=0.022, 0.042, <0.001, and 0.028, respectively), while in multivariate logistic regression analysis, only uni- or bilateral orbital involvement, treatment methods and contrast enhancement pattern on images were significant (r=0.453, 0.897, and 0.556, P=0.038, <0.001 and 0.022, respectively). The survival curves for DFS were obtained. CONCLUSION: The majority of POL are B-cell lymphomas. Unilateral orbital involvement, homogeneous contrast enhancement on images, and the appropriate treatment schemes result to be significant factors for a good prognosis for POL.

show abstract

A pan‐inflammatory microRNA‐cluster is associated with orbital non‐Hodgkin lymphoma and idiopathic orbital inflammation

Cited by 9 publications

References 55 publications

Distinctive Tissue and Serum MicroRNA Profile of IgG4-Related Ophthalmic Disease and MALT Lymphoma

Distinctive Tissue and Serum MicroRNA Profile of IgG4-Related Ophthalmic Disease and MALT Lymphoma

Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment

Predicting the prognosis of primary orbital lymphoma by clinical characteristics and imaging features

Contact Info

Product

Resources

About